Bringing precision medicine to Alzheimer's disease diagnosis and TREATMENT

Following NIH's ATN(V) guidelines, NeuroScope has developed robust quantitative and AI approaches to accurately diagnose patients with Alzheimer's disease from imaging and biomarker data. 

By harnessing the power of multi-source patient data, NeuroScope provides advanced methods for assessing Alzheimer's disease severity, empowering clinicians with precision medicine. 

Accurate diagnosis is crucial for Alzheimer's patients, as they frequently have co-existing neurological conditions that can impact treatment outcomes. NeuroScope leverages clinical and biomarker data to identify these comorbidities for a more comprehensive picture.

Precision medicine starts with precise monitoring. NeuroScope provides clinicians with quantitative, patient-specific insights into treatment response and disease progression, empowering them to tailor treatment plans for optimal outcomes in Alzheimer's patients.

Current Alzheimer's treatments can have a side effect called Amyloid-Related Imaging Abnormalities (ARIA), which is often visually assessed and can vary significantly between patients. NeuroScope addresses this challenge with qARIA, our innovative method for quantifying ARIA to provide a more objective and consistent evaluation.

NeuroScope revolutionizes clinical trials for Alzheimer's drugs by leveraging advanced, quantitative techniques to assess drug effectiveness from imaging, biomarkers, or a powerful combination. This translates to smaller, faster trials with highly reliable data, ultimately reducing the burden on patients while accelerating the path to effective treatments.

Accurate clinical trials rely on precise patient stratification. NeuroScope's quantitative stratification methods ensure homogenous patient groups, minimizing noise in the data and leading to clearer, more reliable results for Alzheimer's drug development.

Delivering drugs to their target in the brain is crucial for neurological diseases. However, the intricate dance of fluids and the vascular system within the brain significantly impacts how a drug distributes. NeuroScope's advanced imaging technologies provide a sophisticated way to quantify these features, offering unprecedented insights into drug pathways and ultimately, improving the development of targeted therapies.